Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



Summit Presents Preclinical DMD Data at 21st Congress of World Muscle Society

06 October 2016: Oxford, UK - Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, announces the presentation of preclinical data at the 21st International Congress of the World Muscle Society, which is taking place in Granada, Spain from 4-8 October 2016.  The data include further findings from Summit's programme to develop tools to measure biomarkers of muscle health for use in patient clinical trials evaluating utrophin modulator therapies.

Read the rest of entry »

Bio-start Confirms Sir Richard Sykes as Chair of Judging Panel

06 October 2016 / London, UK - SynbiCITE and Rainbow Seed Fund today announce that Sir Richard Sykes, Chairman of the Royal Institution of Great Britain, Chairman of Imperial College Healthcare and Chancellor of Brunel University, will act as Chair of judges for the Bio-start competition judging panel in 2017.

Read the rest of entry »

Thermo Fisher Scientific Successfully Launches Science World Event in France

06 October 2016 / London, UK - SynbiCITE and Rainbow Seed Fund today announce that Sir Richard Sykes, Chairman of the Royal Institution of Great Britain, Chairman of Imperial College Healthcare and Chancellor of Brunel University, will act as Chair of judges for the Bio-start competition judging panel in 2017.

Read the rest of entry »

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

05 October 2016: Oxford, UK – Karus Therapeutics (‘Karus’), a leader in the development of innovative, orally-active medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed in a Phase I study for its lead candidate, KA2237.

Read the rest of entry »

Oxford Immunotec Announces Closing of $40 Million in Debt Financing

05 October 2016: Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, today announced that it has entered into an agreement with MidCap Financial (“MidCap”) that provides the Company with $40 million in debt financing, comprised of both a term loan and a revolving line of credit.

Read the rest of entry »

AMSBIO Launches Comprehensive Selection of Products for Wnt Signaling Research

05 October 2016: Abingdon, UK - AMSBIO has launched a comprehensive selection of products for Wnt signaling research including recombinant proteins, stable reporter cell lines, polyclonal antibodies and ELISA assay kits.

Read the rest of entry »

Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration Agreement for European Rights to Summit's Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

04 October 2016: Oxford, UK & Cambridge, USA - Sarepta Therapeutics and Summit Therapeutics plc today announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States ('the licensed territory'), to Summit's utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy ('DMD'). As part of the agreement, Sarepta also obtains an option to license Latin American rights to Summit's utrophin modulator pipeline. Summit retains commercialization rights in all other countries.

Read the rest of entry »

Healx Secures £1.5m from Amadeus Capital and Investors to Combat Rare Diseases

04 October 2016: Cambridge, UK – Healx, an innovative British healthcare company that seeks new uses for existing drugs in the fight against rare diseases has secured an early-stage investment from Amadeus Capital Partners, the global technology investor. Amadeus Capital is investing in a £1.5 million Series A round, alongside renowned healthcare entrepreneur, Jonathan Milner. Board members include bio-tech entrepreneur, Darrin Disley, and drug development leader, David Brown, co-inventor of Viagra.

Read the rest of entry »

Wickham Laboratories Announces Upcoming Webinar on Microbial Limits Testing

04 October 2016: Gosport UK - Join Wickham Laboratories for a Free Webinar on Risks, Regulations and Determining the Best Method for Your Product, 3rd November, 3PM GMT.

Read the rest of entry »

EUSA Pharma Acquires Global Rights to Neuroblastoma Treatment Isqette® (dinutuximab beta) from Apeiron Biologics

04 October 2016: Hemel Hempstead, UK & Vienna, Austria – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced the acquisition of exclusive global commercialization rights to the oncology product Isqette (dinutuximab beta) from Apeiron Biologics.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.